GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B5921 Cyclosporin HSummary: Selective and competitive formyl peptide receptor antagonist
-
B6888 N-Formyl-Met-Leu-PheSummary: formyl peptide receptor 1 (FPR1) agonist
-
B7202 FPR A14Summary: Formyl peptide receptor (FPR) agonist
-
B5178 WKYMVMSummary: Selective agonist for the formyl peptide receptors FPR2 and FPR3
-
B5179 WKYMVmSummary: Selective agonist for the formyl peptide receptors FPR1, FPR2
-
B5283 WRW4Summary: Selective antagonist of formyl peptide receptor 2 (FPR2) signaling
-
B5400 Ac9-25Summary: formyl peptide receptor 1 (FPR1) ligand
-
B5446 MMK 1Summary: human formyl peptide receptor FPR2 agonist
-
B5472 Boc-MLFSummary: formyl peptide receptor 1 (FPR1) antagonist
-
B5656 PBP 10Summary: formyl peptide receptor 2 (FPR2) antagonist